NRXP - NRX Pharmaceuticals, Inc.
IEX Last Trade
1.58
-0.130 -8.228%
Share volume: 331
Last Updated: Thu 26 Dec 2024 03:30:06 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$1.71
-0.13
-7.60%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.67%
1 Month
19.85%
3 Months
-6.55%
6 Months
-41.64%
1 Year
247.35%
2 Year
42.73%
Key data
Stock price
$1.58
DAY RANGE
$1.65 - $1.71
52 WEEK RANGE
$0.47 - $7.33
52 WEEK CHANGE
-$66.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Stephen H. Willard
Region: US
Website: nrxpharma.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nrxpharma.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
NRX Pharmaceuticals, Inc. develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure.
Recent news